Teva Receives CHMP Positive Opinion for DuoResp® Spiromax® for the Treatment of Patients Diagnosed with Asthma and COPD in Europe

[Business Wire] – Teva Pharmaceutical Industries Ltd. announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorization for DuoResp® Spiromax® inhalati more

View todays social media effects on TEVA

View the latest stocks trending across Twitter. Click to view dashboard

See who Teva is hiring next, click here to view